1470 related articles for article (PubMed ID: 7946100)
1. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
[TBL] [Abstract][Full Text] [Related]
2. Immunologic marker paths for seroconversion: single determinations of immunoglobulin A and beta 2-microglobulin are not adequate to estimate time of HIV infection. Multicohort Analysis Project Workshop. Part II.
AIDS; 1994 Jul; 8(7):923-33. PubMed ID: 7946101
[TBL] [Abstract][Full Text] [Related]
3. Improvement of the predictive value of CD4+ lymphocyte count by beta 2-microglobulin, immunoglobulin A and erythrocyte sedimentation rate. The Multicentre Cohort Study Group.
Schwartländer B; Bek B; Skarabis H; Koch J; Burkowitz J; Koch MA
AIDS; 1993 Jun; 7(6):813-21. PubMed ID: 8103341
[TBL] [Abstract][Full Text] [Related]
4. Use of monitored CD4 cell counts: predictions of the AIDS epidemic in Scotland: CD4 Collaborative Group.
AIDS; 1992 Feb; 6(2):213-22. PubMed ID: 1348418
[TBL] [Abstract][Full Text] [Related]
5. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.
O'Brien WA; Hartigan PM; Martin D; Esinhart J; Hill A; Benoit S; Rubin M; Simberkoff MS; Hamilton JD
N Engl J Med; 1996 Feb; 334(7):426-31. PubMed ID: 8552144
[TBL] [Abstract][Full Text] [Related]
6. Progression of HIV infection among injecting drug users: indications for a lower rate of progression among those who have frequently borrowed injecting equipment.
Mientjes GH; van Ameijden EJ; van den Hoek AJ; Goudsmit J; Miedema F; Coutinho RA
AIDS; 1993 Oct; 7(10):1363-70. PubMed ID: 8267910
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.
Messele T; Brouwer M; Girma M; Fontanet AL; Miedema F; Hamann D; Rinke de Wit TF
Clin Immunol; 2001 Feb; 98(2):212-9. PubMed ID: 11161977
[TBL] [Abstract][Full Text] [Related]
8. Secular trends in the survival of HIV-infected homosexual men in Amsterdam and Vancouver estimated from a death-included CD4-staged Markov model.
Hendriks JC; Craib KJ; Veugelers PJ; van Druten HA; Coutinho RA; Schechter MT; van Griensven GJ
Int J Epidemiol; 2000 Jun; 29(3):565-72. PubMed ID: 10869332
[TBL] [Abstract][Full Text] [Related]
9. Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group.
Moore RD; Keruly J; Richman DD; Creagh-Kirk T; Chaisson RE
AIDS; 1992 Jul; 6(7):671-7. PubMed ID: 1503686
[TBL] [Abstract][Full Text] [Related]
10. Use of beta 2-microglobulin level and CD4 lymphocyte count to predict development of acquired immunodeficiency syndrome in persons with human immunodeficiency virus infection.
Anderson RE; Lang W; Shiboski S; Royce R; Jewell N; Winkelstein W
Arch Intern Med; 1990 Jan; 150(1):73-7. PubMed ID: 1967523
[TBL] [Abstract][Full Text] [Related]
11. CD4 surveillance in Scotland: perspectives on severe HIV-related immunodeficiency. CD4 Collaborative Group.
AIDS; 1997 Oct; 11(12):1509-17. PubMed ID: 9342074
[TBL] [Abstract][Full Text] [Related]
12. [Natural history of human immunodeficiency virus infection in a cohort of Chilean patients].
Vial PA; Ferreccio C; Abarca K; Ortiz E; Noriega M; Pérez C; Labarca J; Torres M; Ferrés M; González C; Acuña G
Rev Med Chil; 1996 May; 124(5):525-35. PubMed ID: 9035503
[TBL] [Abstract][Full Text] [Related]
13. Impact of tuberculosis on the course of HIV-infected patients with a high initial CD4 lymphocyte count.
Mañas E; Pulido F; Peña JM; Rubio R; Gonzalez-García J; Costa R; Pérez-Rodríguez E; Del Palacio A
Int J Tuberc Lung Dis; 2004 Apr; 8(4):451-7. PubMed ID: 15141738
[TBL] [Abstract][Full Text] [Related]
14. [The prognostic markers of survival and progression in HIV-1 infection. A study of CD4+ lymphocytes, antigen p24 and viral load during 3 years in a cohort of 251 patients].
Rubio Caballero M; Nogués Biau A; Falguera Sacrest M; Puig Ganau T; Lecha N; Rubio Rivas C
An Med Interna; 2000 Oct; 17(10):533-7. PubMed ID: 11109648
[TBL] [Abstract][Full Text] [Related]
15. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
16. The Edinburgh City Hospital cohort: analysis of enrollment, progression and mortality by baseline covariates.
Brettle RP; McNeil AJ; Gore SM; Bird AG; Leen CS; Richardson A
QJM; 1995 Jul; 88(7):479-91. PubMed ID: 7633874
[TBL] [Abstract][Full Text] [Related]
17. Disease progression and early predictors of AIDS in HIV-seroconverted injecting drug users. The Italian Seroconversion Study.
AIDS; 1992 Apr; 6(4):421-6. PubMed ID: 1616637
[TBL] [Abstract][Full Text] [Related]
18. [Adenosine deaminase (ADA) and beta 2-microglobulin (beta 2M) as discriminating serum markers of progression to AIDS].
Pérez de Oteyza C; Menéndez Martínez MA; Irazábal C; Enríquez de Salamanca R; Pérez Aznar C; Rebollar JL
An Med Interna; 1996 May; 13(5):217-21. PubMed ID: 8767867
[TBL] [Abstract][Full Text] [Related]
19. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection.
Mildvan D; Spritzler J; Grossberg SE; Fahey JL; Johnston DM; Schock BR; Kagan J
Clin Infect Dis; 2005 Mar; 40(6):853-8. PubMed ID: 15736019
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.
Fahey JL; Taylor JM; Detels R; Hofmann B; Melmed R; Nishanian P; Giorgi JV
N Engl J Med; 1990 Jan; 322(3):166-72. PubMed ID: 1967191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
